Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer (SMART)

Clinical Trial ID NCT04276857

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04276857

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.	J Clin Oncol	1997	29.02
2	FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.	N Engl J Med	2011	24.32
3	Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.	N Engl J Med	2013	16.24
4	Pancreatic cancer.	N Engl J Med	2010	13.88
5	Pancreatic cancer.	Lancet	2011	8.54
6	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.	JAMA	2016	2.59
7	Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.	Ann Surg	2015	2.00
8	Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy.	J Vasc Interv Radiol	2014	1.70
9	Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.	J Clin Oncol	2016	0.91
10	Irreversible electroporation: evolution of a laboratory technique in interventional oncology.	Diagn Interv Radiol	2014	0.87
11	Stage III pancreatic cancer and the role of irreversible electroporation.	BMJ	2015	0.80
12	Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma.	J Vasc Interv Radiol	2016	0.75